Melinta Therapeutics
Melinta Therapeutics Announces Termination of Merger Agreement and Tender Offer for Shares of Tetraphase
June 24, 2020 16:02 ET | Melinta Therapeutics
MORRISTOWN, N.J., June 24, 2020 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage antibiotics company, announced that on June 24, 2020, pursuant to the Agreement and...
Melinta Therapeutics
Melinta Therapeutics Enters Into Agreement to Acquire Tetraphase Pharmaceuticals
June 09, 2020 16:02 ET | Melinta Therapeutics
Company Enters Growth Phase in Hospital Market with Support of Deerfield Acquisition to Augment Company’s Core Antibiotic Portfolio  MORRISTOWN, N. J. , June 09, 2020 (GLOBE NEWSWIRE) --...
Melinta Therapeutics
Melinta Therapeutics Confirms Deerfield as Successful Bidder for Company
March 04, 2020 16:03 ET | Melinta Therapeutics
MORRISTOWN, N.J., March 04, 2020 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (the “Company” or “Melinta”), a commercial-stage company focused on the development and commercialization of novel...
Melinta Therapeutics
Melinta Therapeutics Announces Court Approval of Chapter 11 Bidding Procedures
February 13, 2020 16:02 ET | Melinta Therapeutics
Bids due on March 2, 2020 by 4:00 p.m. Eastern Time Company Previously Announced Agreement of its Secured Lenders to Acquire Company as Going Concern, Subject to Higher and Better Offers Company...
Melinta Therapeutics
Melinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit Facility
December 27, 2019 09:02 ET | Melinta Therapeutics
MORRISTOWN, N.J., Dec. 27, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT) (the “Company” or “Melinta”), a commercial-stage company focused on the development and...
Melinta Therapeutics
Melinta Therapeutics Files Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2019
November 12, 2019 17:07 ET | Melinta Therapeutics
MORRISTOWN, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...
Melinta Therapeutics
Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
October 24, 2019 16:02 ET | Melinta Therapeutics
~ Approval Based on Positive Phase III Trial Results of BAXDELA for Treatment of CABP in Adults~ ~ Company Delays Launch of CABP Indication Until Further Visibility Into Liquidity Position ~ ...
Melinta Therapeutics
Melinta Therapeutics Announces Appointment of Jennifer Sanfilippo to Interim Chief Executive Officer and Director
September 03, 2019 16:05 ET | Melinta Therapeutics
MORRISTOWN, N.J., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (Nasdaq: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...
Melinta Therapeutics
Melinta Therapeutics Names David Gill as Chairman and Announces CEO Succession Plan
August 09, 2019 07:31 ET | Melinta Therapeutics
MORRISTOWN, N.J., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...
Melinta Therapeutics
Melinta Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
August 09, 2019 07:30 ET | Melinta Therapeutics
~ Revenue of $16.0 million, Including Net Product Sales of $13.8 million, for the Second Quarter 2019 ~ ~ Reduction of Operating Expenses of 32 Percent, or $16.3 million, Year-Over-Year ~ ...